Policy & Regulation
Rodin Therapeutics Initiates Phase 1 Clinical Trial of a Selective CoREST Inhibitor to Treat Neurologic Diseases
14 December 2018 - - US-based synaptopathies drug developer Rodin Therapeutics has initiated a Phase 1 clinical trial of the company's lead candidate, RDN-929, a potent and selective HDAC-CoREST ...
InterVenn BioSciences Raises USD 9.4m to Help Physicians Detect Early Ovarian Cancer with a Minimally Invasive Test
14 December 2018 - - US-based life sciences and technology company InterVenn BioSciences has received an institutional investment of USD 9.4m led by seasoned biotech investor Genoa Ventures, with part...
Eli Lilly & Incyte partnership wins US FDA's FTD for baricitinib for systemic lupus erythematosus
14 December 2018 - Autoimmune diseases company Eli Lilly and Company (NYSE:LLY) said on the US Food and Drug Administration's (FDA) fast track designation to facilitate the development and expedi...
ESSA Pharma reports financial results for year ended 30 September 2018
14 December 2018 - ESSA Pharma Inc (TSX-V: EPI)(NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported yesterday its financial res...
Janssen Pharmaceutical's psoriasis drug achieves primary endpoint in phase 3 trial
14 December 2018 - Belgium-based Janssen Pharmaceutical's Tremfya (guselkumab) was found to be superior to Cosentyx (secukinumab) for the primary endpoint evaluated at week 48 of a phase three tr...
Aveo Oncology Forges Immuno-Oncology Clinical Collaboration with AstraZeneca
13 December 2018 - - US-based biopharmaceutical company Aveo Oncology (NASDAQ: AVEO) has entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca'...